Lyra Therapeutics (LYRA) EBT (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly EBT of -$6.9 million in Q4 2025, down 16.18% on a QoQ basis from -$6.0 million in Q3 2025, and up 36.67% YoY from -$5.1 million in Q4 2024.
Lyra Therapeutics (LYRA) EBT (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported EBT for 7 consecutive years, with -$6.9 million the latest figure, recorded in Q4 2025.
- EBT for Q4 2025 came in at -$6.9 million, up 36.67% year-over-year; the trailing twelve-month figure through Dec 2025 was -$28.9 million (up 69.05% YoY), and the FY2025 annual result was -$28.9 million, up 69.05% from the prior year.
- EBT for Q4 2025 stood at -$6.9 million, down from -$6.0 million in the prior quarter.
- The five-year high for EBT was -$6.0 million in Q3 2025, with the low at -$48.1 million in Q2 2024.
- A 5-year average of -$14.8 million and a median of -$14.1 million in 2021 frame the typical range for EBT.
- Across the five-year window, EBT plunged 208.34% in 2024 and jumped 84.55% in 2025, its largest moves.
- Lyra Therapeutics' EBT stood at -$13.7 million in 2021, then slipped by 3.89% to -$14.2 million in 2022, then declined by 6.45% to -$15.1 million in 2023, then climbed by 27.52% to -$11.0 million in 2024, then surged by 36.67% to -$6.9 million in 2025.
- The last three EBT figures came in at -$6.9 million (Q4 2025), -$6.0 million (Q3 2025), and -$7.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 81.49 Mn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | -6.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.95 Mn |
| Sep 30, 2025 | -5.98 Mn |
| Jun 30, 2025 | -7.44 Mn |
| Mar 31, 2025 | -8.54 Mn |
| Dec 31, 2024 | -10.97 Mn |
| Sep 30, 2024 | -11.87 Mn |
| Jun 30, 2024 | -48.12 Mn |
| Mar 31, 2024 | -22.44 Mn |
| Dec 31, 2023 | -15.14 Mn |
| Sep 30, 2023 | -15.64 Mn |
| Jun 30, 2023 | -15.61 Mn |
| Mar 31, 2023 | -16.24 Mn |
| Dec 31, 2022 | -14.22 Mn |
| Sep 30, 2022 | -14.77 Mn |
| Jun 30, 2022 | -14.37 Mn |
| Mar 31, 2022 | -11.91 Mn |
| Dec 31, 2021 | -13.69 Mn |
| Sep 30, 2021 | -14.80 Mn |
| Jun 30, 2021 | -14.02 Mn |
| Mar 31, 2021 | -13.34 Mn |